Last reviewed · How we verify
NCT06888648
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Phase 1, PHASE2 trial testing individualized anti-tumor new antigen iNeo-Vac-R01 injection in Pancreatic Cancer Metastatic in 30 participants. Not yet recruiting.
1 April 2027
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 April 2025 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- individualized anti-tumor new antigen iNeo-Vac-R01 injection — full drug profile →
- mFOLFIRINOX Treatment Regimen — full drug profile →
- Sintilimab injection — full drug profile →
Conditions studied
- Pancreatic Cancer Metastatic — all drugs for Pancreatic Cancer Metastatic →
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
Sponsor
Zhejiang University
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer Metastatic or Pancreatic Cancer Non-resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm phase I/II clinical study to evaluate the effectiveness of evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard chemotherapy regimens for the treatment of patients with advanced pancreatic cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.
Forenzo C, Arnold N, Larsen J. · · 2025 · cited 1× · PMID 40762456 · DOI 10.1080/17435889.2025.2542110
Verify or expand the search:
- PubMed search for NCT06888648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of individualized anti-tumor new antigen iNeo-Vac-R01 injection
Trials testing the same drug.
- NCT06995105 — Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06956716 — Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma · Phase 1, PHASE2 · recruiting
- NCT06888674 — Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Pancreatic Cancer Metastatic
Currently open trials in the same condition.
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07040228 — A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Tr · Phase 1, PHASE2 · recruiting
- NCT06840067 — Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer. · NA · recruiting
- NCT06752811 — Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer · Phase 3 · recruiting
- NCT06946420 — SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy · Phase 3 · active not recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06888648 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing